Biological markers and schizophrenia

被引:16
作者
Copolov, D
Crook, J
机构
[1] Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia
[2] NIMH, Clin Brain Disorders Branch, Bethesda, MD 20892 USA
关键词
biological markers; dopamine; homovanillic acid; review; schizophrenia; smooth pursuit eye movements; ventricles;
D O I
10.1046/j.1440-1614.2000.00778.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The delivery of biological markers for schizophrenia would greatly assist preventative strategies by identifying at-risk individuals who could then be monitored and treated in a manner with a view to minimising subsequent morbidity. This paper aims to present a selection of biological measures that may indicate risk of schizophrenia. Method: A selective and brief review is provided of intensively studied putative markers, including enlarged cerebral ventricles, dopamine D-2 receptor density, amphetamine-stimulated central nervous system dopamine release, plasma homovanillic acid and smooth pursuit eye tracking dysfunction. Results: A number of biological measures have been reported to be correlated with schizophrenia. Conclusions: Presently, none of these measures has satisfactory performance characteristics in terms of predictive validity, noninvasiveness, ease of testing and low cost that would enable their widespread use. However, a few have potential for further investigation and development.
引用
收藏
页码:S108 / S112
页数:5
相关论文
共 48 条
[31]   Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective [J].
Lieberman, JA .
BIOLOGICAL PSYCHIATRY, 1999, 46 (06) :729-739
[32]   Psychobiologic correlates of treatment response in schizophrenia [J].
Lieberman, JA ;
Alvir, JM ;
Koreen, A ;
Geisler, S ;
Chakos, M ;
Sheitman, B ;
Woerner, M .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (03) :S13-S21
[34]   STUDIES OF CATECHOLAMINE METABOLISM IN SCHIZOPHRENIA PSYCHOSIS .1. [J].
MAAS, JW ;
CONTRERAS, SA ;
MILLER, AL ;
BERMAN, N ;
BOWDEN, CL ;
JAVORS, MA ;
SELESHI, E ;
WEINTRAUB, S .
NEUROPSYCHOPHARMACOLOGY, 1993, 8 (02) :97-109
[35]   Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations [J].
Maas, JW ;
Bowden, CL ;
Miller, AL ;
Javors, MA ;
Funderburg, LG ;
Berman, N ;
Weintraub, ST .
SCHIZOPHRENIA BULLETIN, 1997, 23 (01) :147-154
[36]   First-episode neuroleptic-free schizophrenics: Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment [J].
Nagaoka, S ;
Iwamoto, N ;
Arai, H .
BIOLOGICAL PSYCHIATRY, 1997, 41 (08) :857-864
[37]  
NORDSTROM AL, 1995, AM J PSYCHIAT, V152, P1444
[38]   Implications of brain imaging for the management of schizophrenia [J].
Nyberg, S ;
Nilsson, U ;
Okubo, Y ;
Halldin, C ;
Farde, L .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 :S15-S20
[39]  
PICKAR D, 1990, ARCH GEN PSYCHIAT, V47, P641
[40]   STRUCTURAL BRAIN ABNORMALITIES IN THE MAJOR PSYCHOSES - A QUANTITATIVE REVIEW OF THE EVIDENCE FROM COMPUTERIZED IMAGING [J].
RAZ, S ;
RAZ, N .
PSYCHOLOGICAL BULLETIN, 1990, 108 (01) :93-108